Advanced Enzyme Technologies Q2 Net Profit Grows 14% to Rs 51.2 Crore

Revenue for the quarter hit Rs 214.5 crore with EBITDA margins expanding to 34%.

Reader Takeaway: Strong growth in bio-processing and animal nutrition drives results, while B2C expansion remains a key focus.

What just happened

Advanced Enzyme Technologies posted a consolidated revenue of Rs 214.5 crore for Q2 FY27, a 16% increase over the Rs 184.5 crore reported in the same quarter last year. The company's net profit reached Rs 51.2 crore, up 14% from Rs 44.7 crore in Q2 FY26. Operating efficiency improved, with EBITDA rising 20% to Rs 72.1 crore, yielding a healthy EBITDA margin of 34%.

Why this matters

The company saw exceptional momentum in its non-human nutrition verticals. The bio-processing segment grew 43% year-on-year, bolstered by a 48% jump in the food business. Similarly, the animal nutrition segment recorded a significant 37% revenue increase. These figures indicate successful diversification beyond the core human nutrition segment, which grew at a more measured 6%.

The backstory

Advanced Enzyme Technologies has consistently maintained a debt-free balance sheet. The company is currently shifting its strategic focus toward the Indian B2C market with its 'Wellfa' brand, aiming to replicate its successful US-based nutritional product model. Additionally, the company is actively developing bio-catalysis solutions for API manufacturers, with several products now in advanced plant-level trials.

Risks to watch

Investors should closely monitor the scalability of the 'Wellfa' B2C brand in the competitive Indian nutraceutical landscape. Additionally, any delays in plant-level trials for bio-catalysis products or challenges in identifying suitable inorganic growth targets could impact long-term valuation premiums.

What to track next

The primary focus for shareholders remains the execution of inorganic growth strategies to bolster front-end marketing and the continued integration of B2C product lines into the domestic market.